Thus, our findings can potentially expand the application of both CX-5461 and TOP1 inhibitors such as topotecan in clinical trials to the 50% of HGSC patients who have HR-proficient tumours and to patients with HR-deficient tumours that have acquired chemotherapeutic resistance due to restored HR. This evidence concerns the gene TOP1 and neoplasm.